Literature DB >> 32381479

Measles and rubella IgG seroprevalence in persons 6 month-35 years of age, Mongolia, 2016.

Francisco Nogareda1, Nyamaa Gunregjav2, Amarzaya Sarankhuu3, Enkhtuya Munkhbat2, Enkhbaatar Ichinnorov4, Pagbajabyn Nymadawa5, Kathleen Wannemuehler6, Mick N Mulders7, Jose Hagan8, Minal K Patel9.   

Abstract

BACKGROUND: In 2015-2016, Mongolia experienced an unexpected large measles outbreak affecting mostly young children and adults. After two nationwide vaccination campaigns, measles transmission declined. To determine if there were any remaining immunity gaps to measles or rubella in the population, a nationally representative serosurvey for measles and rubella antibodies was conducted after the outbreak was over.
METHODS: A nationwide, cross-sectional, stratified, three-stage cluster serosurvey was conducted in November-December 2016. A priori, four regional strata (Ulaanbaatar, Western, Central, and Gobi-Eastern) and five age strata (6 months-23 months, 2-7 years, 8-17 years, 18-30 years, and 31-35 years) were created. Households were visited, members interviewed, and blood specimens were collected from age-appropriate members. Blood specimens were tested for measles immunoglobulin G (IgG) and rubella IgG (Enzygnost® Anti-measles Virus/IgG and Anti-rubella Virus/IgG, Siemens, Healthcare Diagnostics Products, GmbH Marburg, Germany). Factors associated with seropositivity were evaluated.
RESULTS: Among 4598 persons aged 6 months to 35 years participating in the serosurvey, 94% were measles IgG positive and 95% were rubella IgG positive. Measles IgG seropositivity was associated with increasing age and higher education. Rubella IgG seropositivity was associated with increasing age, higher education, smaller household size, receipt of MMR in routine immunization, residence outside the Western Region, non-Muslim religious affiliation, and non-Kazakh ethnicity. Muslim Kazakhs living in Western Region had the lowest rubella seroprevalence of all survey participants.
CONCLUSIONS: Nationally, high immunity to both measles and rubella has been achieved among persons 1-35 years of age, which should be sufficient to eliminate both measles and rubella if future birth cohorts have ≥ 95% two dose vaccination coverage. Catch-up vaccination is needed to close immunity gaps found among some subpopulations, particularly Muslim Kazakhs living in Western Region.
Copyright © 2020. Published by Elsevier Ltd.

Entities:  

Keywords:  Measles; Mongolia; Rubella; Seroprevalence

Mesh:

Substances:

Year:  2020        PMID: 32381479      PMCID: PMC8881742          DOI: 10.1016/j.vaccine.2020.04.024

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  27 in total

1.  Measles antibody: reevaluation of protective titers.

Authors:  R T Chen; L E Markowitz; P Albrecht; J A Stewart; L M Mofenson; S R Preblud; W A Orenstein
Journal:  J Infect Dis       Date:  1990-11       Impact factor: 5.226

2.  Linkages between maternal education and childhood immunization in India.

Authors:  Kriti Vikram; Reeve Vanneman; Sonalde Desai
Journal:  Soc Sci Med       Date:  2012-03-28       Impact factor: 4.634

Review 3.  Biological feasibility of measles eradication.

Authors:  William J Moss; Peter Strebel
Journal:  J Infect Dis       Date:  2011-07       Impact factor: 5.226

4.  Framework for verifying elimination of measles and rubella.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2013-03-01

5.  Gaps in the 2010 measles SIA coverage among migrant children in Beijing: evidence from a parental survey.

Authors:  Xiaojiang Hu; Suowei Xiao; Binli Chen; Zhihong Sa
Journal:  Vaccine       Date:  2012-07-20       Impact factor: 3.641

6.  Impact of measles supplementary immunization activities on reaching children missed by routine programs.

Authors:  Allison Portnoy; Mark Jit; Stéphane Helleringer; Stéphane Verguet
Journal:  Vaccine       Date:  2017-11-23       Impact factor: 3.641

7.  Maternal education and child immunization: the mediating roles of maternal literacy and socioeconomic status.

Authors:  Saliu Adejumobi Balogun; Hakeem Abiola Yusuff; Kehinde Quasim Yusuf; Abdulah Mohammed Al-Shenqiti; Mariam Temitope Balogun; Prudence Tettey
Journal:  Pan Afr Med J       Date:  2017-04-24

8.  Epidemiological characteristics and trends of a Nationwide measles outbreak in Mongolia, 2015-2016.

Authors:  Oyunchimeg Orsoo; Yu Mon Saw; Enkhbold Sereenen; Buyanjargal Yadamsuren; Ariunsanaa Byambaa; Tetsuyoshi Kariya; Eiko Yamamoto; Nobuyuki Hamajima
Journal:  BMC Public Health       Date:  2019-02-15       Impact factor: 3.295

9.  Measles and rubella immunity in the population of Bhutan, 2017.

Authors:  Sonam Wangchuk; Francisco Nogareda; Namgay Tshering; Lekey Khandu; Sonam Pelden; Kathleen Wannemuehler; Sonam Wangdi; Ugyen Wangchuk; Mick Mulders; Tshewang Tamang; Minal K Patel
Journal:  Vaccine       Date:  2019-09-06       Impact factor: 3.641

Review 10.  A review of testing used in seroprevalence studies on measles and rubella.

Authors:  Wayne Dimech; Mick N Mulders
Journal:  Vaccine       Date:  2016-06-20       Impact factor: 3.641

View more
  1 in total

1.  Evaluating the effect of measles and rubella mass vaccination campaigns on seroprevalence in India: a before-and-after cross-sectional household serosurvey in four districts, 2018-2020.

Authors:  Manoj V Murhekar; Nivedita Gupta; Alvira Z Hasan; Muthusamy Santhosh Kumar; V Saravana Kumar; Christine Prosperi; Gajanan N Sapkal; Jeromie Wesley Vivian Thangaraj; Ojas Kaduskar; Vaishali Bhatt; Gururaj Rao Deshpande; Ullas Padinjaremattathil Thankappan; Avi Kumar Bansal; Sanjay L Chauhan; Gangandeep Singh Grover; Arun Kumar Jain; Ragini N Kulkarni; Santanu Kumar Sharma; Itta K Chaaithanya; Sanchit Kharwal; Sunil K Mishra; Neha R Salvi; Sandeep Sharma; Nilanju P Sarmah; R Sabarinathan; Augustine Duraiswamy; D Sudha Rani; K Kanagasabai; Abhishek Lachyan; Poonam Gawali; Mitali Kapoor; Arpit Kumar Shrivastava; Saurabh Kumar Chonker; Bipin Tilekar; Babasaheb V Tandale; Mohammad Ahmad; Lucky Sangal; Amy Winter; Sanjay M Mehendale; William J Moss; Kyla Hayford
Journal:  Lancet Glob Health       Date:  2022-11       Impact factor: 38.927

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.